Adalimumab Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
ABBV | C | AbbVie Inc. | -1.28 | |
VTRS | F | Viatris Inc. | -0.48 | |
CHRS | F | Coherus BioSciences, Inc. | 0.00 |
Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
Compare ETFs
- Adalimumab
Adalimumab, sold under the brand name Humira, among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is administered by injection under the skin.Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, multiple sclerosis, heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2017, it was the 169th most commonly prescribed medication in the United States, with more than three million prescriptions.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles